Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update
12:02pm, Friday, 04'th Aug 2023
Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Misses Revenue Estimates
10:32am, Thursday, 03'rd Aug 2023
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to loss of $1.33 per share a year ago.
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates
07:30am, Thursday, 27'th Jul 2023
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics l
Intellia Therapeutics: The Future Is Here
11:18pm, Wednesday, 26'th Jul 2023
Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. NTLA is on track toward key data and regulatory catalysts. Early clinical data in HAE and
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
05:55pm, Monday, 24'th Jul 2023
Growth investors are frequently looking for biotech stocks to buy. So what exactly is a biotech stock?
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
08:08am, Thursday, 20'th Jul 2023
The biotechnology sector is the reason why treatments and diagnostics for all mankind have experienced exponential advances. If you are passionate about value investing, you must understand that one o
3 Biotech Stocks to Buy for Long-Term Gains
07:01am, Thursday, 13'th Jul 2023
Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated
1 Cathie Wood Stock That Could Double Your Money
09:30am, Thursday, 06'th Jul 2023
Cathie Wood's Ark Innovation fund has identified CRISPR/Cas 9 gene editing as a $2 trillion a year opportunity. Her flagship fund has been buying shares of Intellia Therapeutics this year.
3 Monster Stocks in the Making to Buy Right Now
06:07am, Sunday, 25'th Jun 2023
Axsome Therapeutics' pipeline features multiple potentially big winners. CRISPR Therapeutics could be at the beginning of a long-term success story.
Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?
04:45pm, Friday, 23'rd Jun 2023
Intellia Therapeutics won't be commercializing a drug within a year. It also won't be reporting pivotal clinical trial data.
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?
09:45am, Wednesday, 21'st Jun 2023
Cathie Wood has been loading up on Intellia Therapeutics. She's also trimming her holdings of CRISPR Therapeutics, a major competitor.
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money.
05:50am, Tuesday, 20'th Jun 2023
Alibaba has tremendous growth opportunities in AI. Intellia Therapeutics' gene-editing therapies hold the potential to be big winners.
Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why.
10:00am, Monday, 19'th Jun 2023
Intellia Therapeutics is developing gene-editing cures for hereditary diseases. It's succeeding with its early-stage clinical work, but the real tests are yet to come.
3 Cathie Wood Investments That Could Deliver Superior Returns
09:15am, Saturday, 17'th Jun 2023
Intellia Therapeutics and CRISPR Therapeutics are clinical-stage gene-editing companies. Block is one of the primary fintech companies.
2 Growth Stocks Cathie Wood Is Buying Hand Over Fist
05:41am, Thursday, 15'th Jun 2023
Exchange-traded funds run by Ark Invest bought heaps of growth stocks in the first half of June. Intellia Therapeutics is developing new CRISPR-based therapies that can edit in vivo the genes that lea
